Webinars and Sponsored Roundtables — Register Now
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Sysmex
| Company | Sysmex |
|---|---|
| Instrument name/First year sold | Sysmex CS-5100 System/2016 |
| Contact | Krishna Ram |
| City, State | Lincolnshire, IL |
| Phone | 847-996-4500 |
| Website | |
| List price/Model type | —/floor standing |
| No. of units in clinical use in U.S./Outside U.S. | >100/>1, 000 (worldwide) |
| Composition of installs: Hospital lab/Reference lab/Other | 95%/5%/— |
| Targeted daily, monthly, annual test volume | daily: >300; monthly: >9, 000; annual: >110, 000 |
| Operational type | continuous random access |
| Country where analyzer designed/Manufactured | Japan/Japan |
| Company manufactures instrument | yes |
| FDA-approved clotting-based tests | PT, APTT, fibrinogen, thrombin time, reptilase time, factors II, V, VII, VIII, IX, XI, and XII, lupus screen, lupus confirm, protein C, factor V Leiden |
| FDA-approved chromogenic tests | factor VIII chromogenic, antithrombin, protein C, anti-Xa, heparin (UFH and LMWH), free protein S antigen, alpha-2-antiplasmin, plasminogen |
| FDA-approved immunologic tests | D-dimer, vWF activity (GP1bM), vWF antigen |
| Other FDA-approved tests | — |
| User-defined tests in clinical use | factor XIII chromogenic RUO, platelet aggregation testing RUO |
| Methodologies supported | clot detection, optical; turbidimetric; chromogenic; immunologic (immunoturbidimetric) |
| Number of different measured assays onboard simultaneously | 60 |
| Number of different assays programmed and calib. at one time | 60 |
| No. of user-definable (open) channels/No. active simultaneously | 80, 000/60 |
| Factor assays require manual manipulation or dilutions | — |
| Test throughput per hour/Assay run time | 400 (2 tests in throughput)/1–10 min. (avg. 5 min.) |
| Design of sample-handling system | 10-tube position sample rack, with a maximum of 10 × racks |
| Operates on whole blood or spun plasma | spun plasma |
| Reagent type | self-contained single-use vials; open reagent system (liquid, lyophilized [reconstituted manually]) |
| Reagent barcode-reading capability | yes, for all tests |
| No. of reagent containers held onboard/Reagents ready to use | 45/variable (reagent specific) |
| Reagent lot tracking/Reagent inventory/Reagents refrigerated onboard | yes/yes/yes (10°C ± 2°C) |
| Reagents, consumables loaded without interrupting testing | yes (reagents and consumables) |
| Instrument uses proprietary or third-party reagents | user’s option (same capabilities when third-party reagents used) |
| Maximum time same lot number of reagents can be used | 18 months |
| Walkaway capability/Walkaway duration | yes/100 specimens or 1, 000 tests |
| Min.–max. specimen volume that can be aspirated at one time | 5–500 µL |
| Min. sample volume required for PT/PTT/Factor VIII activity | reaction cuvettes, CA clean I, CA clean II |
| Primary tube sampling supported/Pierces caps on primary tubes | yes/yes |
| Accommodates most standard tube sizes/Nonstandard sizes | yes/yes |
| Sample barcode-reading capability/Autodiscrimination | yes (Interleaved 2 of 5, Code 39, Code 128)/yes |